HCW Biologics forms JV Trimmune with WY Biotech; receives $3.5M upfront plus equity worth $3.5M

HCW Biologics Inc.

Exclusive worldwide license for HCW11-006 in vivo applications; option for Greater China rights to HCW9302.
Upfront cash fee of $3.5M ($1.75M paid now, remainder due by March 6, 2026) plus co-founder equity valued at ~$3.5M.
Eligible for development milestone payments, double-digit royalties, and share of future transaction proceeds.
HCW Biologics retains royalty-free option to reclaim Americas rights after Phase 1; Phase 1 trial expected H1 2027.
JV Trimmune backed by CITIC Medical Fund and TigerMed; expenses for Phase 1 in China paid by Trimmune.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

HCW Biologics Inc. entered into a license with WY Biotech Co., Ltd. (effective 2026-02-13).

Action: entry
Agreement: license
Counterparty: WY Biotech Co., Ltd.
Effective: 2026-02-13

Exact text from the filing

On February 13, 2026, HCW Biologics Inc. and WY Biotech Co., Ltd. (“WY Biotech”), a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell therapies, today jointly announced the commencement of an exclusive worldwide license agreement covering the development and commercialization rights for certain in vivo applications for one of HCW Biologics’ proprietary molecules, HCW11-006.

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

HCW Biologics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-049953

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.